Medical Writing Authors and Authorship Attribution, advocacy, disposable authors, corporate ghosts and cultural assimilation: new themes in the ethical critique of commercial medical literature
emwa-spring-2016png

Volume 25, Issue 1 - Authors and Authorship

Attribution, advocacy, disposable authors, corporate ghosts and cultural assimilation: new themes in the ethical critique of commercial medical literature

Abstract

This interview provides solutions to some of the common pitfalls that face medical writers when working with large teams. Practical tips are provided on key topics including manuscript planning, agreeing on key messages and the use of figures, tables and other contents, deciding on the criteria for authorship, and dealing with contributors who fall short of their commitments.

Download the full article

References

  1. Huth EJ, Case K. The URM: twentyfive years old. Science Editor 2004; 27: 17-21.
  2. Rennie D, Yank V, Emanuel L. When authorship fails. A proposal to make contributors accountable. JAMA 1997; 278: 579-585.
  3. Rennie D. Integrity in scientific publishing. Health Serv Res 2010; 45: 885-896.
  4. International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations). Available from: http://www.icmje.org/recommendations/
  5. Matheson A. Corporate science and the husbandry of scientific and medical knowledge by the pharmaceutical industry. BioSocieties 2008; 3: 355– 382.
  6. Sismondo S. Key opinion leaders and the corruption of medical knowledge: what the Sunshine Act will and won’t cast light on. J Law Med Ethics. 2013;41:635-43.
  7. Moynihan R. Key opinion leaders: independent experts or drug representatives in disguise? BMJ. 2008;336:1402-3.
  8. White Paper: Key Opinion Leader Identification and Selection. A Pharma Matters Report. Thomson Reuters, January 2009. Available from: http://www.slideshare.net/driceman/kol-management?related=1
  9. Matheson A. The disposable author: how pharmaceutical marketing is embraced within medicine’s scholarly literature. Hastings Center Report 2016; 10.1002/hast.576.
  10. Wittek MR, Williams MJ, Carlson AM. Evidence development and publication planning: strategic process. Curr Med Res Opin. 2009;25:2723-7.
  11. Sismondo S. Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Medicine 2007; 4: e286.
  12. Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, et al. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Ann Intern Med. 2015;163:461-4.
  13. Hoekman J, Frenken K, de Zeeuw D, Heerspink HL. The geographical distribution of leadership in globalized clinical trials. PLoS One 2012; 7: e45984.
  14. Hirsch LJ. Conflicts of interest, authorship, and disclosures in industryrelated scientific publications: the tort bar and editorial oversight of medical journals. Mayo Clin Proc. 2009;84: 811-21.
  15. Davidoff, F, C.D. DeAngelis, J.M. Drazen, M.G. Nicholls, J. Hoey et al. 2001. Sponsorship, authorship, and accountability. New England Journal of Medicine. 345:825-826.
  16. DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA. 2004 Sep 15;292(11):1363-4
  17. Lessig L. “Institutional corruption” defined. J Law Med Ethics 2013; 41: 2-4.
  18. Foucault, M. (1980). The confession of the flesh. In M. Foucault (C. Gordon, Ed.), Power/knowledge: Selected interviews and other writings, 194–228. Brighton: Harvester Press.P 195.
  19. Horton R. The Dawn of McScience. New York Review of Books. March 11 2004.
  20. Drazen JM. Revisiting the commercialacademic interface. N Engl J Med 2014;372;19:1853-4.

Search

Articles

Authors and Authorship
Letter from the Editor
President’s Message
Ghostwriting prevalence among AMWA and EMWA members (2005 to 2014)
The sun never sets on transparency
GPP3 – what is it, why is it necessary and what is new?
Attribution, advocacy, disposable authors, corporate ghosts and cultural assimilation: new themes in the ethical critique of commercial medical literature
Perspective from a leading scientific author: An interview with Professor Ruth Roberts on authors and authoring
Authorship of clinical trial documents
Project management in medical publication writing: A less explored avenue in pharmaceutical companies and clinical research organisations
Never say never! Returning to full-time employment after freelancing
Fifth EMWA freelance business survey
Journal Watch
In the Bookstores
The Webscout
Regulatory Writing: Authorship issues in regulatory documents
English Grammar and Style
Medical Communication
Lingua Franca and Beyond
Gained in Translation
Medical Writing Teaching
Profile: An interview with Phil Leventhal
EMWA’s 2016 Webinar Programme
Out on our own

Member Login

Links

The Write Stuff Archive Contact Instructions for Authors Feature Article Template (Word) Journal Policies

Editoral Board

Editor-in-Chief:

Co-Editor:

Managing Editor

show all +

Associate Editors:

Section Editors:

Ad-hoc Editors:

  • Amy Whereat (SpeaktheSpeech Consulting, Asnieres sur Seine, France)

Editor Emeritus: